Eintrag weiter verarbeiten
An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure
Gespeichert in:
| Zeitschriftentitel: | Circulation Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Circulation Research, 112, 2013, 5, S. 816-825 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
Penn, Marc S. Mendelsohn, Farrell O. Schaer, Gary L. Sherman, Warren Farr, MaryJane Pastore, Joseph Rouy, Didier Clemens, Ruth Aras, Rahul Losordo, Douglas W. Penn, Marc S. Mendelsohn, Farrell O. Schaer, Gary L. Sherman, Warren Farr, MaryJane Pastore, Joseph Rouy, Didier Clemens, Ruth Aras, Rahul Losordo, Douglas W. |
|---|---|
| author |
Penn, Marc S. Mendelsohn, Farrell O. Schaer, Gary L. Sherman, Warren Farr, MaryJane Pastore, Joseph Rouy, Didier Clemens, Ruth Aras, Rahul Losordo, Douglas W. |
| spellingShingle |
Penn, Marc S. Mendelsohn, Farrell O. Schaer, Gary L. Sherman, Warren Farr, MaryJane Pastore, Joseph Rouy, Didier Clemens, Ruth Aras, Rahul Losordo, Douglas W. Circulation Research An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure Cardiology and Cardiovascular Medicine Physiology |
| author_sort |
penn, marc s. |
| spelling |
Penn, Marc S. Mendelsohn, Farrell O. Schaer, Gary L. Sherman, Warren Farr, MaryJane Pastore, Joseph Rouy, Didier Clemens, Ruth Aras, Rahul Losordo, Douglas W. 0009-7330 1524-4571 Ovid Technologies (Wolters Kluwer Health) Cardiology and Cardiovascular Medicine Physiology http://dx.doi.org/10.1161/circresaha.111.300440 <jats:sec> <jats:title> <jats:underline>Rationale:</jats:underline> </jats:title> <jats:p>Preclinical studies indicate that adult stem cells induce tissue repair by activating endogenous stem cells through the stromal cell-derived factor-1:chemokine receptor type 4 axis. JVS-100 is a DNA plasmid encoding human stromal cell-derived factor-1.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Objective:</jats:underline> </jats:title> <jats:p>We tested in a phase 1, open-label, dose-escalation study with 12 months of follow-up in subjects with ischemic cardiomyopathy to see if JVS-100 improves clinical parameters.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Methods and Results:</jats:underline> </jats:title> <jats:p>Seventeen subjects with ischemic cardiomyopathy, New York Heart Association class III heart failure, with an ejection fraction ≤40% on stable medical therapy, were enrolled to receive 5, 15, or 30 mg of JVS-100 via endomyocardial injection. The primary end points for safety and efficacy were at 1 and 4 months, respectively. The primary safety end point was a major adverse cardiac event. Efficacy end points were change in quality of life, New York Heart Association class, 6-minute walk distance, single photon emission computed tomography, N-terminal pro-brain natruretic peptide, and echocardiography at 4 and 12 months. The primary safety end point was met. At 4 months, all of the cohorts demonstrated improvements in 6-minute walk distance, quality of life, and New York Heart Association class. Subjects in the 15- and 30-mg dose groups exhibited improvements in 6-minute walk distance (15 mg: median [range]: 41 minutes [3–61 minutes]; 30 mg: 31 minutes [22–74 minutes]) and quality of life (15 mg: –16 points [+1 to –32 points]; 30 mg: –24 points [+17 to –38 points]) over baseline. At 12 months, improvements in symptoms were maintained.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Conclusions:</jats:underline> </jats:title> <jats:p>These data highlight the importance of defining the molecular mechanisms of stem cell-based tissue repair and suggest that overexpression of stromal cell-derived factor-1 via gene therapy is a strategy for improving heart failure symptoms in patients with ischemic cardiomyopathy.</jats:p> </jats:sec> An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure Circulation Research |
| doi_str_mv |
10.1161/circresaha.111.300440 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjcmVzYWhhLjExMS4zMDA0NDA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjcmVzYWhhLjExMS4zMDA0NDA |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2013 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2013 |
| issn |
0009-7330 1524-4571 |
| issn_str_mv |
0009-7330 1524-4571 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
penn2013anopenlabeldoseescalationstudytoevaluatethesafetyofadministrationofnonviralstromalcellderivedfactor1plasmidtotreatsymptomaticischemicheartfailure |
| publishDateSort |
2013 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
Circulation Research |
| source_id |
49 |
| title |
An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_unstemmed |
An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_full |
An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_fullStr |
An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_full_unstemmed |
An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_short |
An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_sort |
an open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure |
| topic |
Cardiology and Cardiovascular Medicine Physiology |
| url |
http://dx.doi.org/10.1161/circresaha.111.300440 |
| publishDate |
2013 |
| physical |
816-825 |
| description |
<jats:sec>
<jats:title>
<jats:underline>Rationale:</jats:underline>
</jats:title>
<jats:p>Preclinical studies indicate that adult stem cells induce tissue repair by activating endogenous stem cells through the stromal cell-derived factor-1:chemokine receptor type 4 axis. JVS-100 is a DNA plasmid encoding human stromal cell-derived factor-1.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>
<jats:underline>Objective:</jats:underline>
</jats:title>
<jats:p>We tested in a phase 1, open-label, dose-escalation study with 12 months of follow-up in subjects with ischemic cardiomyopathy to see if JVS-100 improves clinical parameters.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>
<jats:underline>Methods and Results:</jats:underline>
</jats:title>
<jats:p>Seventeen subjects with ischemic cardiomyopathy, New York Heart Association class III heart failure, with an ejection fraction ≤40% on stable medical therapy, were enrolled to receive 5, 15, or 30 mg of JVS-100 via endomyocardial injection. The primary end points for safety and efficacy were at 1 and 4 months, respectively. The primary safety end point was a major adverse cardiac event. Efficacy end points were change in quality of life, New York Heart Association class, 6-minute walk distance, single photon emission computed tomography, N-terminal pro-brain natruretic peptide, and echocardiography at 4 and 12 months. The primary safety end point was met. At 4 months, all of the cohorts demonstrated improvements in 6-minute walk distance, quality of life, and New York Heart Association class. Subjects in the 15- and 30-mg dose groups exhibited improvements in 6-minute walk distance (15 mg: median [range]: 41 minutes [3–61 minutes]; 30 mg: 31 minutes [22–74 minutes]) and quality of life (15 mg: –16 points [+1 to –32 points]; 30 mg: –24 points [+17 to –38 points]) over baseline. At 12 months, improvements in symptoms were maintained.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>
<jats:underline>Conclusions:</jats:underline>
</jats:title>
<jats:p>These data highlight the importance of defining the molecular mechanisms of stem cell-based tissue repair and suggest that overexpression of stromal cell-derived factor-1 via gene therapy is a strategy for improving heart failure symptoms in patients with ischemic cardiomyopathy.</jats:p>
</jats:sec> |
| container_issue |
5 |
| container_start_page |
816 |
| container_title |
Circulation Research |
| container_volume |
112 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792339415083778061 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:47:44.653Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=An+Open-Label+Dose+Escalation+Study+to+Evaluate+the+Safety+of+Administration+of+Nonviral+Stromal+Cell-Derived+Factor-1+Plasmid+to+Treat+Symptomatic+Ischemic+Heart+Failure&rft.date=2013-03-01&genre=article&issn=1524-4571&volume=112&issue=5&spage=816&epage=825&pages=816-825&jtitle=Circulation+Research&atitle=An+Open-Label+Dose+Escalation+Study+to+Evaluate+the+Safety+of+Administration+of+Nonviral+Stromal+Cell-Derived+Factor-1+Plasmid+to+Treat+Symptomatic+Ischemic+Heart+Failure&aulast=Losordo&aufirst=Douglas+W.&rft_id=info%3Adoi%2F10.1161%2Fcircresaha.111.300440&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792339415083778061 |
| author | Penn, Marc S., Mendelsohn, Farrell O., Schaer, Gary L., Sherman, Warren, Farr, MaryJane, Pastore, Joseph, Rouy, Didier, Clemens, Ruth, Aras, Rahul, Losordo, Douglas W. |
| author_facet | Penn, Marc S., Mendelsohn, Farrell O., Schaer, Gary L., Sherman, Warren, Farr, MaryJane, Pastore, Joseph, Rouy, Didier, Clemens, Ruth, Aras, Rahul, Losordo, Douglas W., Penn, Marc S., Mendelsohn, Farrell O., Schaer, Gary L., Sherman, Warren, Farr, MaryJane, Pastore, Joseph, Rouy, Didier, Clemens, Ruth, Aras, Rahul, Losordo, Douglas W. |
| author_sort | penn, marc s. |
| container_issue | 5 |
| container_start_page | 816 |
| container_title | Circulation Research |
| container_volume | 112 |
| description | <jats:sec> <jats:title> <jats:underline>Rationale:</jats:underline> </jats:title> <jats:p>Preclinical studies indicate that adult stem cells induce tissue repair by activating endogenous stem cells through the stromal cell-derived factor-1:chemokine receptor type 4 axis. JVS-100 is a DNA plasmid encoding human stromal cell-derived factor-1.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Objective:</jats:underline> </jats:title> <jats:p>We tested in a phase 1, open-label, dose-escalation study with 12 months of follow-up in subjects with ischemic cardiomyopathy to see if JVS-100 improves clinical parameters.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Methods and Results:</jats:underline> </jats:title> <jats:p>Seventeen subjects with ischemic cardiomyopathy, New York Heart Association class III heart failure, with an ejection fraction ≤40% on stable medical therapy, were enrolled to receive 5, 15, or 30 mg of JVS-100 via endomyocardial injection. The primary end points for safety and efficacy were at 1 and 4 months, respectively. The primary safety end point was a major adverse cardiac event. Efficacy end points were change in quality of life, New York Heart Association class, 6-minute walk distance, single photon emission computed tomography, N-terminal pro-brain natruretic peptide, and echocardiography at 4 and 12 months. The primary safety end point was met. At 4 months, all of the cohorts demonstrated improvements in 6-minute walk distance, quality of life, and New York Heart Association class. Subjects in the 15- and 30-mg dose groups exhibited improvements in 6-minute walk distance (15 mg: median [range]: 41 minutes [3–61 minutes]; 30 mg: 31 minutes [22–74 minutes]) and quality of life (15 mg: –16 points [+1 to –32 points]; 30 mg: –24 points [+17 to –38 points]) over baseline. At 12 months, improvements in symptoms were maintained.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Conclusions:</jats:underline> </jats:title> <jats:p>These data highlight the importance of defining the molecular mechanisms of stem cell-based tissue repair and suggest that overexpression of stromal cell-derived factor-1 via gene therapy is a strategy for improving heart failure symptoms in patients with ischemic cardiomyopathy.</jats:p> </jats:sec> |
| doi_str_mv | 10.1161/circresaha.111.300440 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE2MS9jaXJjcmVzYWhhLjExMS4zMDA0NDA |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2013 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2013 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0009-7330, 1524-4571 |
| issn_str_mv | 0009-7330, 1524-4571 |
| language | English |
| last_indexed | 2024-03-01T15:47:44.653Z |
| match_str | penn2013anopenlabeldoseescalationstudytoevaluatethesafetyofadministrationofnonviralstromalcellderivedfactor1plasmidtotreatsymptomaticischemicheartfailure |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | 816-825 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | Circulation Research |
| source_id | 49 |
| spelling | Penn, Marc S. Mendelsohn, Farrell O. Schaer, Gary L. Sherman, Warren Farr, MaryJane Pastore, Joseph Rouy, Didier Clemens, Ruth Aras, Rahul Losordo, Douglas W. 0009-7330 1524-4571 Ovid Technologies (Wolters Kluwer Health) Cardiology and Cardiovascular Medicine Physiology http://dx.doi.org/10.1161/circresaha.111.300440 <jats:sec> <jats:title> <jats:underline>Rationale:</jats:underline> </jats:title> <jats:p>Preclinical studies indicate that adult stem cells induce tissue repair by activating endogenous stem cells through the stromal cell-derived factor-1:chemokine receptor type 4 axis. JVS-100 is a DNA plasmid encoding human stromal cell-derived factor-1.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Objective:</jats:underline> </jats:title> <jats:p>We tested in a phase 1, open-label, dose-escalation study with 12 months of follow-up in subjects with ischemic cardiomyopathy to see if JVS-100 improves clinical parameters.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Methods and Results:</jats:underline> </jats:title> <jats:p>Seventeen subjects with ischemic cardiomyopathy, New York Heart Association class III heart failure, with an ejection fraction ≤40% on stable medical therapy, were enrolled to receive 5, 15, or 30 mg of JVS-100 via endomyocardial injection. The primary end points for safety and efficacy were at 1 and 4 months, respectively. The primary safety end point was a major adverse cardiac event. Efficacy end points were change in quality of life, New York Heart Association class, 6-minute walk distance, single photon emission computed tomography, N-terminal pro-brain natruretic peptide, and echocardiography at 4 and 12 months. The primary safety end point was met. At 4 months, all of the cohorts demonstrated improvements in 6-minute walk distance, quality of life, and New York Heart Association class. Subjects in the 15- and 30-mg dose groups exhibited improvements in 6-minute walk distance (15 mg: median [range]: 41 minutes [3–61 minutes]; 30 mg: 31 minutes [22–74 minutes]) and quality of life (15 mg: –16 points [+1 to –32 points]; 30 mg: –24 points [+17 to –38 points]) over baseline. At 12 months, improvements in symptoms were maintained.</jats:p> </jats:sec> <jats:sec> <jats:title> <jats:underline>Conclusions:</jats:underline> </jats:title> <jats:p>These data highlight the importance of defining the molecular mechanisms of stem cell-based tissue repair and suggest that overexpression of stromal cell-derived factor-1 via gene therapy is a strategy for improving heart failure symptoms in patients with ischemic cardiomyopathy.</jats:p> </jats:sec> An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure Circulation Research |
| spellingShingle | Penn, Marc S., Mendelsohn, Farrell O., Schaer, Gary L., Sherman, Warren, Farr, MaryJane, Pastore, Joseph, Rouy, Didier, Clemens, Ruth, Aras, Rahul, Losordo, Douglas W., Circulation Research, An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure, Cardiology and Cardiovascular Medicine, Physiology |
| title | An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_full | An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_fullStr | An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_full_unstemmed | An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_short | An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| title_sort | an open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure |
| title_unstemmed | An Open-Label Dose Escalation Study to Evaluate the Safety of Administration of Nonviral Stromal Cell-Derived Factor-1 Plasmid to Treat Symptomatic Ischemic Heart Failure |
| topic | Cardiology and Cardiovascular Medicine, Physiology |
| url | http://dx.doi.org/10.1161/circresaha.111.300440 |